Company research
Regen BioPharma Inc
CIK 1589150Updated Sep 26, 2026
RGBP price & chart
Loading TradingView…
OTC:RGBP on TradingView ↗In the news
No coverage from other publishers is available.
SEC disclosures
Recent filings
10-Q filing
NT 10-Q filing
Entry into a Material Definitive Agreement · Changes in Registrant's Certifying Accountant · Other Events
Items 1.01, 4.01, 8.01, 9.01
10-Q filing
Unregistered Sales of Equity Securities
Items 3.02
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 274,628Source | 161,084Source | 353,617Source | 559,002Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 69,555Source | 716Source | — | 51,204Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 204,873Source | 94,873Source | 0Source | 254,273Source |
| Assets, CurrentUSD | 274,628Source | 143,351Source | 131,037Source | 336,422Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 6,555,811Source | 5,378,455Source | 5,457,617Source | 8,595,061Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 3,939Source | 527Source | 352Source | 503,150Source |
| Additional Paid in CapitalUSD | 15,628,062Source | 15,403,050Source | 13,908,141Source | 11,581,499Source |
| Retained Earnings (Accumulated Deficit)USD | -21,691,620Source | -20,417,118Source | -19,748,863Source | -20,905,369Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -222,580Source | -204,847Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | -6,281,183Source | -5,217,372Source | -5,104,000Source | -8,036,059Source |
| Liabilities and EquityUSD | 274,628Source | 161,084Source | 353,617Source | 559,002Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 6,555,811Source | 5,378,455Source | 5,308,003Source | 8,595,061Source |
| Accounts Payable, CurrentUSD | 1,714Source | 29,668Source | 29,674Source | 28,799Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,838,230Source | 1,664,827Source | — | — |
| Deferred Revenue, CurrentUSD | 1,338,611Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | 13,048Source | — | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 110,000Source | 94,874Source | -254,272Source | 41,082Source |
| Increase (Decrease) in Accounts PayableUSD | 821Source | -7Source | 875Source | -62,705Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -383,591Source | -751,536Source | -173,917Source | 606,921Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | 25,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 452,430Source | 631,215Source | 243,750Source | -94,036Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 68,839Source | -120,321Source | — | -675,957Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 121,037Source | — |
| Additional Financial Items | ||||
| Amortization of Debt Issuance Costs and DiscountsUSD | 52,148Source | -28,998Source | 864Source | 71,067Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | -675,528Source | -4,091Source | 2,151,755Source | 3,340,683Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | 0Source | -1,828Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 1,150Source | -95,019Source |
| General and Administrative ExpenseUSD | 75,113Source | 58,920Source | 44,975Source | 28,055Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | 158,286Source | 72,445Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -1,274,502Source | -668,255Source | 1,156,507Source | 2,443,531Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -668,255Source | 1,023,508Source | 2,227,034Source |
| Nonoperating Income (Expense)USD | — | — | 1,843,456Source | — |
| Operating ExpensesUSD | 575,101Source | 653,781Source | — | — |
| Proceeds from Issuance of Common StockUSD | 58,200Source | 563,722Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 236,561Source | 236,560Source | — | — |
| Operating Income (Loss)USD | -338,540Source | -417,221Source | -686,950Source | -339,605Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -1,274,502Source | -668,255Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -1,274,502Source | -668,255Source | 1,156,507Source | 2,443,531Source |
| Earnings Per Share, BasicUSD per share | -0.05Source | -0.16Source | 0.29Source | — |
| Earnings Per Share, DilutedUSD per share | -0.05Source | -0.16Source | 0.29Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 23,521,970Source | 4,110,265Source | 3,536,963Source | 4,703,768,705Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 23,521,970Source | 4,110,265Source | 3,536,963Source | — |
| Interest Expense (non-operating)USD | 158,286Source | 72,445Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | — | — | 923,509Source | 575,122Source |
| General and Administrative ExpenseUSD | 75,113Source | 58,920Source | 44,975Source | 28,055Source |
| Interest and Other IncomeUSD | — | — | 0Source | — |
| Interest ExpenseUSD | — | — | 58,584Source | 138,720Source |
| Interest Income (Expense), NetUSD | — | — | — | 455Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -668,255Source | 1,023,508Source | 2,227,034Source |
| Nonoperating Income (Expense)USD | — | — | 1,843,456Source | — |
| Operating ExpensesUSD | 575,101Source | 653,781Source | — | — |
| Other Cost and Expense, OperatingUSD | — | — | 60,000Source | — |
| Research and Development ExpenseUSD | 11,725Source | 153,685Source | 212,297Source | 158,138Source |